CN113577047A - Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome - Google Patents
Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome Download PDFInfo
- Publication number
- CN113577047A CN113577047A CN202110199352.4A CN202110199352A CN113577047A CN 113577047 A CN113577047 A CN 113577047A CN 202110199352 A CN202110199352 A CN 202110199352A CN 113577047 A CN113577047 A CN 113577047A
- Authority
- CN
- China
- Prior art keywords
- apoc3
- pcos
- preparation
- insulin
- ovarian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 78
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229940125396 insulin Drugs 0.000 title claims abstract description 26
- 102000004877 Insulin Human genes 0.000 title claims abstract description 25
- 108090001061 Insulin Proteins 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 10
- 230000001276 controlling effect Effects 0.000 title claims abstract description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 10
- 229940093265 berberine Drugs 0.000 claims description 9
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229960003105 metformin Drugs 0.000 claims description 4
- 108010027070 Apolipoproteins C Proteins 0.000 claims description 3
- 102000018655 Apolipoproteins C Human genes 0.000 claims description 3
- 231100000489 sensitizer Toxicity 0.000 claims 2
- 230000002611 ovarian Effects 0.000 abstract description 39
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 31
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 28
- 210000001672 ovary Anatomy 0.000 abstract description 13
- 229940122355 Insulin sensitizer Drugs 0.000 abstract description 8
- 102100030970 Apolipoprotein C-III Human genes 0.000 abstract description 7
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 46
- 241000700159 Rattus Species 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000001993 wax Substances 0.000 description 11
- 108050006400 Cyclin Proteins 0.000 description 10
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000002503 granulosa cell Anatomy 0.000 description 5
- 201000010066 hyperandrogenism Diseases 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960004329 metformin hydrochloride Drugs 0.000 description 4
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009933 reproductive health Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 101100228149 Drosophila melanogaster Trl gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 101100370408 Helicobacter pylori (strain ATCC 700392 / 26695) trl gene Proteins 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000852812 Rattus norvegicus Insulin receptor Proteins 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- MGJURKDLIJVDEO-UHFFFAOYSA-N formaldehyde;hydrate Chemical compound O.O=C MGJURKDLIJVDEO-UHFFFAOYSA-N 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000006679 metabolic signaling pathway Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
The invention discloses application of a preparation for regulating and controlling the expression level of ApoC3 in preparing a medicament for preventing or treating insulin-resistant polycystic ovary syndrome. According to the invention, the ovarian tissue and granular cells of a PCOS patient are in a proliferation state, the ovarian tissue ApoC3 of the PCOS patient is highly expressed, and the ovarian tissue ApoC3 of a PCOS model rat is highly expressed and is closely related to local insulin resistance of the PCOS ovary, and further, the application of an insulin sensitizer to the preparation of a medicine for preventing or treating insulin-resistant polycystic ovarian syndrome can be used for regulating the expression level of ApoC3, so that the APOC3 protein in the ovary can be down-regulated, and the IR resistance condition of the ovarian tissue of the model rat can be improved.
Description
The technical field is as follows:
the invention belongs to the field of biological medicines, and particularly relates to application of a preparation for regulating and controlling the expression level of ApoC3 in preparation of a medicine for preventing or treating insulin-resistant polycystic ovarian syndrome.
Background art:
firstly, the more serious glycolipid metabolic disturbance exists in the PCOS patient with the insulin resistance type, the early intervention is performed, and the method is important for improving the reproductive health of the PCOS patient.
Insulin Resistance (IR) and hyperinsulinemia are the main pathological bases of patients with Polycystic Ovary Syndrome (PCOS), play a key role in the occurrence and development of PCOS, and 50-70% of PCOS patients have IR and hyperinsulinemia through domestic and overseas researches. The insulin resistant state (PCOS-IR) of patients with PCOS not only affects their fertility, but is also associated with a range of health problems, including thin or closed menstrual cycle, abnormal uterine bleeding, spontaneous abortion, hypertensive disorders of pregnancy, type 2 diabetes, cardiovascular disorders, endometrial cancer, and the like. The U.S. endocrine Association issued PCOS treatment guidelines in 2013 indicate that: infertility is a prominent clinical problem in patients with PCOS; there are also many obstetrical complications such as gestational diabetes, preeclampsia, etc. in PCOS-IR patients, who are at 2-6 times higher risk of type 2 diabetes, cardiovascular disease, endometrial cancer than PCOS patients who are not associated with IR. The international evidence-based guideline for PCOS in 2018 suggests: PCOS is a disease affecting public health. Our earlier studies also found that: the PCOS patient with the insulin resistance type has more serious glycolipid metabolic disturbance, and the insulin resistance of the PCOS patient is intervened as soon as possible, so that the method has important significance for improving the reproductive health of women.
II, apolipoprotein C-III can be used as a molecular marker for diagnosing the insulin resistance state of a PCOS patient.
The ApoC3 gene is located in chromosome 11A 1/CIII/AIV gene cluster, has a full length of 3.1kb and encodes ApoC3 protein. ApoC3 protein is a glycoprotein with 79 amino acids, which is mainly synthesized in the liver and a small amount in the small intestine of human body, and mainly regulates the decomposition and metabolism of triacylglycerol lipoprotein (TRLS). ApoC3 acts as a lipoprotein lipase (LPL) inhibitor and affects lipid metabolism by inhibiting the activities of lipase, hepatic lipase, cholesterol-egg phosphatidyl transferase. Many researchers have suggested that ApoC3 is excessive, and that it inhibits the binding of lipoprotein to low-density lipoprotein receptor, and also inhibits the binding of lipoprotein to TRLs and their remnant, and inhibits the effective binding of receptor to very low-density lipoprotein (VLDL) and chylomicron (DM), and causes lipid metabolism disorder, visceral fat accumulation, obesity, hypertriglyceridemia, type 2 diabetes, and the like.
Third, PCOS patients have ovarian local IR, and the IR is closely related to high-expression ApoC3, so that ovulation dysfunction is caused.
Over the last 20 years, more and more studies have shown that insulin resistance and compensatory hyperinsulinemia are one of the important characteristic changes of PCOS, and that abnormalities in insulin metabolism or insulin signaling pathway are central to the pathogenesis of PCOS. PCOS-IR can increase the responsiveness of the pituitary to gonadotropin-releasing hormone, leading to increased luteinizing hormone and androgen secretion, disrupting normal function of the hypothalamus-pituitary-ovarian axis, and is critically associated with hyperandrogenism, reproductive disorders, and metabolic syndrome. Several studies have shown that in women with PCOS, loss of insulin activity in classical target organs (adipose tissue and skeletal muscle, etc.) leads to insulin resistance. PCOS has both ovarian local IR, such as ovarian granulosa cell IR, affecting ovarian local glucose metabolism, cholesterol uptake, steroid hormone production, and cell division proliferation. The research shows that the change of insulin signal transduction molecules after the receptor exists in the ovarian granulosa cells of a PCOS patient results in the change of downstream kinase activity, the reduction of insulin signal transduction and the promotion of local insulin resistance of the ovary. It can be seen that the complex mechanism of insulin activity deficiency can also be expressed in the ovarian part, which is the main content of our study. The signal transduction pathways of insulin in cells include a metabolic pathway regulating glucose metabolism, a mitogenic pathway causing cell division and proliferation, and the like. Local IR of ovary shows that the metabolic action promoting pathway of insulin in cell is damaged, and the division promoting pathway is amplified, so that the volume of ovary is increased, follicle development is stopped, ovulation is disturbed, and the local hyperandrogenism state of ovary is caused, and reproductive disorder is caused. We found earlier that: ovarian tissue and granulosa cells are in a proliferative state in patients with PCOS.
The invention content is as follows:
the invention aims to provide application of a preparation for regulating and controlling the expression level of ApoC3 in preparing a medicament for preventing or treating insulin-resistant polycystic ovary syndrome.
Preferably, the agent for regulating the expression level of ApoC3 is an agent for reducing the expression level of ApoC 3.
Further preferably, the agent for reducing the expression level of ApoC3 is an insulin sensitizer.
Preferably, the insulin sensitizer can be metformin or berberine.
According to the invention, the ovarian tissue and granular cells of a PCOS patient are in a proliferation state, the ovarian tissue ApoC3 of the PCOS patient is highly expressed, and the rat ovarian tissue ApoC3 of a PCOS model is highly expressed and closely related to the local insulin resistance of the PCOS ovary, and further, the application of an insulin sensitizer to the preparation of a medicine for preventing or treating insulin resistance polycystic ovarian syndrome can be used for down-regulating the APOC3 protein expression in the ovary and improving the IR resistance condition of the rat ovarian tissue of the model, so that the preparation for regulating and controlling the ApoC3 expression level can be applied to the preparation of the medicine for preventing or treating insulin resistance type polycystic ovarian syndrome.
Description of the drawings:
FIG. 1 shows the immunohistochemical method and Western blot detection of PCNA expression, where A is the immunohistochemical detection of PCNA expression, B is the Westernblot detection of PCNA expression, and C is the Westernblot detection of caspase3 expression.
FIG. 2 shows that ApoC3 protein is highly expressed (HE X40) in ovarian tissue of patients with PCOS-IR, ApoC3 is highly expressed in A.PCOS-IR ovarian granulosa cells, and ApoC3 is lowly expressed in B.PCOS-NIR ovarian tissue;
fig. 3 shows PCOS model group and control group rat vaginal epithelial cells (a. model group, b. control group);
FIG. 4 shows that the insulin and HOMA-IR of model rats are higher than those of control rats (p < 0.01);
FIG. 5 is a graph showing that the IR resistance of ovarian tissues of model rats improved by insulin sensitizers (high, medium and low doses of berberine and metformin), with a concomitant decrease in the expression of rat ovarian ApoC 3.
The specific implementation mode is as follows:
the following examples are intended to further illustrate the invention, but not to limit it.
Example 1:
materials and methods
1. Collection of clinical specimens
Due to the high heterogeneity of PCOS, the diagnostic criteria are divergent and the project group adopted the diagnostic criteria recommended by the European society for human reproduction and embryo and American society for reproductive medicine (ESHRE/ASRM) Lutecan specialist conference in 2003:
(1) dilute or no ovulation;
(2) the clinical manifestations of hyperandrogenism and/or hyperandrogenism;
(3) the ultrasound shows that the ovary is a polycystic ovary (more than 12 follicles with the diameter of 2-9 mm are arranged on one side or two sides of the ovary, and/or the volume of the ovary is more than 10 ml);
(4) and 2 of the 3 above, and excluding other hyperandrogenic diseases such as congenital adrenal cortical hyperplasia, cushing's syndrome, androgen-secreting tumors.
Since diagnosis of PCOS requires exclusion of other related hyperandrogenism diseases, screening of PCOS patients was performed by professional researchers following the special red specialist conference.
The case inclusion criteria were as follows:
(1) the diagnosis standard of polycystic ovarian syndrome is met;
(2) women between 18-45 years of age;
(3) during the treatment period, other western medicines are not used for treatment;
(4) informed consent, volunteer subjects, and observers can be tracked.
The case exclusion criteria were as follows:
(1) those who do not meet the diagnostic criteria for polycystic ovarian syndrome;
(2) women under 18 or over 45 years old, or women in gestation or lactation;
(3) serious cardiovascular diseases, liver diseases, kidney diseases, blood system diseases, lung diseases or serious diseases affecting the survival of the patients, such as tumors or AIDS and the like;
(4) patients with mental or legal disabilities;
(5) patients with endocrine dysfunction such as adrenal gland, thyroid gland, and pituitary gland;
(6) patients suspected of having or determined to have a history of alcohol, drug abuse;
the PCOS insulin resistance group (experimental group) was selected for 30 cases, and the PCOS non-insulin resistance group (control group) was selected for 30 cases, with the age and weight of the patients matched with those in the PCOS insulin resistance group; two groups of patients underwent laparoscopic wedge resection of the ovaries, and the tissues of the ovaries that were removed in a wedge shape were taken for study. Before collecting the samples, the patients were informed of the consent of the ethical committees of hospitals, and the approval numbers of the ethical committees were: 201401011, and signs a surgical consent with the patient. When an ovarian tissue sample is collected in a laparoscopic surgery, the size of the ovarian tissue sample is one tenth of that of the whole ovarian tissue, a tissue similar to a pyramid-like structure is taken on the surface of the ovarian tissue, and the tissue comprises granular cells, theca cells, oocytes, interstitial cells and other various structures. The operation will be performed by a gynecologic endocrine master physician qualified for type IV laparoscopic practice at the women and young health care institute of guangdong province, to ensure the accuracy and representativeness of the clinical specimen collection.
2. Ovarian histopathology and immunohistochemistry
A. Tissue slice preparation
Paraffin embedding of tissue blocks
The endometrial tissue obtained by biopsy was fixed with 4% formaldehyde solution (preparation method: 40% formaldehyde solution and water at a ratio of 1: 9). The fixed time is preferably 12-24 h. Washing the tissue block in a fixed container with running water for 24 hr, sequentially dehydrating with 70% alcohol and 80% alcohol for 2 hr, 90% alcohol for 1 hr, 95% alcohol for 40min, anhydrous alcohol I for 40min, and anhydrous alcohol II for 30 min. And the tissue can be placed in 70% alcohol overnight. The dehydrated tissue is directly immersed in xylene clearing agent (xylene I, xylene II), and each clearing time is 10 min. Then, immersing the tissue into soft wax I for about 1h by adopting paraffin wax with the temperature of 56-58 ℃, and then immersing into soft wax II for 40 min; hard wax I for 40min and hard wax II for 1 h. (the general wax dipping time is 3-4h), the melting point of the soft wax is 45-50 ℃, and the melting point of the hard wax is 55-60 ℃. And finally, injecting the wax liquid into an embedding hard tool, quickly and flatly placing the tissue block into the wax liquid, righting and paving the tissue block, and then moving the tissue block to a cooling table to solidify the tissue block and the wax liquid together. (hard wax fixation type)
b Paraffin section
The excessive paraffin around the specimen is cut off before slicing (the process is called as 'block trimming'), but the paraffin cannot be kept too little, otherwise, the tissue is easy to damage, and the slicing is difficult when the specimen is sliced continuously. The slice thickness is typically 5 μm. Coating a layer of protein glycerol on a clean glass slide, and then baking for 1-2 hours in a constant temperature box at 60 ℃ until the glass slide is dried; if the tissue is stripped, a layer of egg white can be coated for fixation. The pasted sheet is placed in a clean glass sheet box and stored in a refrigerator at 4 ℃ for standby.
B. Immunohistochemical moiety
a dewaxing and hydration
Prior to deparaffinization, the tissue sections should be left to bake for 20min at room temperature for 60min or in an incubator at 60 ℃. Then placing the tissue slices in xylene to soak for 10min, and soaking for 10min after replacing xylene; then soaking in absolute ethanol, 95% ethanol and 70% ethanol for 5min respectively, and washing with PBS for 5min twice. Then preparing fresh 3% H2O2 with distilled water or PBS, sealing at room temperature for 5-10 min, washing with PBS for 3 times, each time for 2 min.
b embedding
Antigen retrieval for formalin fixed paraffin embedded tissue sections. Boiling and heat repairing, heating in an electric furnace or a water bath, heating 0.01M sodium citrate buffer solution (pH6.0) to about 95 ℃, placing the tissue slices into the heated tissue slices for heating for 10-15 min, and cooling the tissue slices to room temperature by using tap water after heating so as to take out the slices. After washing with PBS for 5min, 5% BSA blocking solution was added dropwise and blocked at room temperature for 15 min. And (5) throwing off redundant liquid without washing. Then, primary antibody was added dropwise at 4 ℃ overnight (4 ℃ overnight followed by rewarming at room temperature for 45 min). The next morning was washed 3 times with PBS for 2min each. Then, a poly-HRP-labeled anti-rabbit/mouse IgG secondary antibody is added dropwise, and incubation is carried out for 1h at room temperature. Then washed 3 times with PBS for 2min each.
c color development
And (3) developing with a DAB developing kit or a self-prepared developer (the developing degree is mastered under a mirror), and stopping with distilled water immediately when the background color is light when the target signal is observed to be dark. Counterstaining with hematoxylin for 20s, washing with distilled water for 2 times and 2min each time. Then, the slices are put into 50%, 70%, 80%, 90%, 95% and 100% ethanol in sequence for dehydration for 2min each time. The sections were then placed in 100% xylene for 10min to clear. Finally, 50ul of neutral resin is used for sealing, and the product is stored at room temperature.
3. As a result:
human tissue sample caspase3 and PCNA detection
(1) And selecting 30 PCOS patients and 30 non-PCOS ovarian tissues for research, extracting total protein, and detecting the protein expression amount of caspase3 by using Western blot, wherein the result shows that the expression amount of clear caspase3 in the PCOS group is lower than that in the normal group, and the apoptosis amount in the PCOS ovarian tissues is less than that in the normal group. PCNA expression is detected by an immunohistochemical method and a Westernblot respectively, and immunohistochemical results show that: the expression of PCNA in patients with PCOS was increased compared to the normal group (reddish brown), because PCNA was correlated with the degree of cell proliferation, and an increase in the expression amount of PCNA indicates an increase in cell proliferation in PCOS compared to the normal group. Western blot detection tissues show that the expression level of PCNA in PCOS tissues is higher than that of normal groups, and the result is consistent with that of immunohistochemistry. GAPDH is an internal reference, two groups of caspase3 and PCNA are counted in gray scale, and the PCOS group is obviously higher than the control and has statistical significance. Error bars represent standard errors, P < 0.05. FIG. 1 shows a schematic view of a
(2) And early-stage preliminary experiments are used for carrying out immunohistochemical research on ovarian tissues of PCOS patients: ApoC3 protein was found to be highly expressed in ovarian tissue from patients with PCOS-IR, as shown in FIG. 2, where A shows that ApoC3 protein was highly expressed in both nuclei and cytoplasm of ovarian granulosa cells in ovarian tissue from patients with PCOS-IR, and the staining was dark brown-yellow; b shows that the ApoC3 in the nucleus and cytoplasm of the ovarian granular cells of the PCOS-NIR patient is low in expression. Immunohistochemical results suggest: ApoC3 may be involved in PCOS ovarian local insulin resistance.
Example 2: establishment of PCOS-IR rat model
Materials and methods
1. Laboratory animal
80 21-day-old female SD rats were raised in a clean-grade manner at a constant temperature of 25 ℃ (50% humidity) from the center of medical laboratory animals in Guangdong province. The 12-hour illumination (6: 00-18: 00) and 12-hour darkness (18: 00-6: 00) are performed alternately. Food and water were taken freely.
2. Experimental materials and instruments
DHEA, sesame oil, common feed (processed by Guangdong province medical laboratory animal center), glucose, 0.9% physiological saline, an Elisa kit, a Rui-Ji's staining kit, a glucometer (Sanuo), blood glucose test paper, an optical microscope, a centrifuge and the like.
3. Method of producing a composite material
3.1 model making method for rat animal model selecting 21-day-old SD female rat, dividing into model group and blank control group, 15 control groups and 65 model groups randomly according to random number table method. After grouping, 0.2ml (6mg/100g) of Dehydroepiandrosterone (DHEA) solution dissolved in sesame oil for injection was subcutaneously injected into the back of the neck of the rat in the model group, and 0.2ml of sesame oil for injection was subcutaneously injected into the back of the neck of the rat in the blank control group for 49 days continuously. Rats were weighed every three days.
3.2 method for evaluating success of mold making
3.2.1 vaginal epithelial cells in rats
And observing the vaginal shedding cytological changes of the rats continuously and daily by a Rui-Ji's staining method 10 days before the molding is finished, wherein the vaginal epithelial cells are in a keratinized state for 10 days, and the rats are PCOS rats successfully induced.
The specific experimental method comprises the following steps: dipping a little physiological saline water by using a sterile cotton swab, inserting the cotton swab into a vagina of a rat, slightly twisting, taking out the cotton swab, smearing mucus with vaginal epithelial cells on a glass slide along the same direction, naturally drying, manufacturing two glass slides for each rat every day, uniformly smearing 3-4 drops of a Rui-Ji's staining reagent A for 30-60s, adding 6-10 drops of a reagent B, staining for 10min, washing with tap water, naturally drying, and observing the vaginal epithelial cells under an optical microscope of 40 times and 100 times respectively.
3.2.2 rat fasting blood glucose and fasting insulin detection: 10 mice were randomly selected from each of the rats of the successful PCOS model and the blank group, fasted at 8 nights, and orbital venous blood of the rats was taken at 8 next morning for Fasting blood-glucose (FBG) and insulin-insulin (FINS) detection. Blood glucose levels were measured by the glucose oxidase method (roche glucometer), and Insulin (INS) was measured by the Enzyme linked immunosorbent assay (ELISA). According to the dosage of 2g/kg, rats are intragastrically filled with 50% glucose, a drop of blood is taken from the tail of the rat 30min, 60min and 120min after the glucose administration, the blood sugar of the rat is monitored by a glucometer, an OGTT curve is drawn, and the area under the curve is calculated. And taking 1ml of blood from orbital vein at 60,120min, placing in a drying tube containing anticoagulant, placing on ice, centrifuging for 15min (2500 rpm) after the sampling is finished on the day, carefully collecting supernatant, and detecting serum insulin by ELISA method. HOMA-IR (HOMEOSTASIS model assessment of insulin resistance, HOMA-IR) was calculated as FBG (mmol/L). times.FINS (m U/L)/22.5.
4. Results of animal experiments
PCOS-IR rat ovarian tissue ApoC3 protein is highly expressed, and the use of insulin sensitizer can improve the model rat IR state, and the ovarian tissue ApoC3 protein expression is reduced.
1. We successfully established a PCOS-IR rat model by the subcutaneous injection of dehydroepiandrosterone (dissolved in sesame oil) method. The results showed that the vaginal epithelial cells of the model group rats were in a cornified state for 10 days, with no apparent estrous cycle, while the control group rats had an estrous cycle. The PCOS-IR rat model was suggested to be successfully established, as shown in FIG. 3.
2. The fasting insulin value and HOMA-IR index of the rats in the model group (PCOS-IR group) are obviously higher than those in the control group; the fasting insulin level, 1h and 2h of insulin after glucose administration of the rats in the model group are far higher than those of the rats in the control group, and p is less than 0.01, which prompts the successful establishment of a PCOS-IR rat model, and is shown in figure 4.
3. Western Blot to detect the expression of APOC3 protein in the ovarian tissues of rats in each group:
experimental methods
60 PCOS-IR rats were randomized into groups of 12 rats: a model group, a berberine low-dose group, a berberine middle-dose group, a berberine high-dose group and a metformin hydrochloride positive control group.
The control group adopts insulin sensitizer metformin hydrochloride (500mgbid), and the equivalent dose of the rat is converted according to the conversion coefficient method of the animal kilogram body weight dose. The rats in the treatment group are respectively subjected to intragastric administration intervention with berberine of high dose (162mg/kg), medium dose (81mg/kg) and low dose (40.2mg/kg), 2ml of metformin hydrochloride solution (45mg/kg) is administered once a day for one time, and the metformin group is administered with 2ml of metformin hydrochloride solution (45mg/kg) for one day. The administration was continued for 28 days.
High expression of ApoC3 protein in PCOS-IR rat ovarian tissue, and improved IR resistance in rat ovarian tissue model using insulin sensitizers (high, medium and low doses of berberine and metformin), with a concomitant decrease in rat ovarian ApoC3 expression, as shown in FIG. 5.
APOC3 protein: the results show that compared with the normal group, the APOC3 protein expression level of the model group is remarkably up-regulated (P <0.01), and the APOC3 protein expression can be down-regulated by the high-dose and low-dose groups (P <0.05, P < 0.01). Medium doses down-regulated APOC3 protein expression, but showed no significant difference (P > 0.05). (Note: 1. Normal group; 2. Positive drug (metformin) group; 3. model group; 4. Low dose berberine group; 5. Medium dose berberine group; 6. high dose berberine group).
Claims (4)
1. Application of a preparation for regulating and controlling the expression level of ApoC3 in preparing a medicament for preventing or treating insulin-resistant polycystic ovarian syndrome.
2. The use of claim 1 wherein the agent that modulates the expression of ApoC3 is an agent that reduces the expression of ApoC 3.
3. The use of claim 2 wherein the agent that reduces the expression of ApoC3 is an insulin sensitiser.
4. The use according to claim 3, wherein the insulin sensitiser is metformin or berberine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110199352.4A CN113577047A (en) | 2021-02-22 | 2021-02-22 | Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110199352.4A CN113577047A (en) | 2021-02-22 | 2021-02-22 | Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113577047A true CN113577047A (en) | 2021-11-02 |
Family
ID=78238065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110199352.4A Pending CN113577047A (en) | 2021-02-22 | 2021-02-22 | Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113577047A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023241565A1 (en) * | 2023-02-02 | 2023-12-21 | 广东省妇幼保健院 | Use of reagent for detecting content of apoc3 protein in preparation of reagent for predicting development of oocytes |
WO2024032680A1 (en) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | Method and use of epigenetic editing target |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105699656A (en) * | 2016-01-25 | 2016-06-22 | 李荔 | Application of reagent for detecting content of ApoC3 protein in preparation of kit for diagnosing and predicating insulin resisting type PCOS (Poly Cystic Ovarian Syndrome) |
US20190076380A1 (en) * | 2011-01-07 | 2019-03-14 | Elcelyx Therapeutics, Inc. | Biguanide Compositions and Methods of Treating Metabolic Disorders |
US20190255028A1 (en) * | 2016-04-19 | 2019-08-22 | Keto Patent Group, Inc. | Administration of berberine metabolites |
CN111662302A (en) * | 2020-07-07 | 2020-09-15 | 诸城市林家村中心卫生院 | Compounds and compositions thereof for the treatment of polycystic ovarian syndrome |
-
2021
- 2021-02-22 CN CN202110199352.4A patent/CN113577047A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190076380A1 (en) * | 2011-01-07 | 2019-03-14 | Elcelyx Therapeutics, Inc. | Biguanide Compositions and Methods of Treating Metabolic Disorders |
CN105699656A (en) * | 2016-01-25 | 2016-06-22 | 李荔 | Application of reagent for detecting content of ApoC3 protein in preparation of kit for diagnosing and predicating insulin resisting type PCOS (Poly Cystic Ovarian Syndrome) |
US20190255028A1 (en) * | 2016-04-19 | 2019-08-22 | Keto Patent Group, Inc. | Administration of berberine metabolites |
CN111662302A (en) * | 2020-07-07 | 2020-09-15 | 诸城市林家村中心卫生院 | Compounds and compositions thereof for the treatment of polycystic ovarian syndrome |
Non-Patent Citations (2)
Title |
---|
吕霄等: "盐酸小檗碱对多囊卵巢综合征伴胰岛素抵抗的疗效及对血浆颗粒蛋白前体水平的影响", 《中国临床研究》 * |
杨滢等: "血清载脂蛋白C3在胰岛素抵抗疾病中的研究进展", 《实用医学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024032680A1 (en) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | Method and use of epigenetic editing target |
WO2023241565A1 (en) * | 2023-02-02 | 2023-12-21 | 广东省妇幼保健院 | Use of reagent for detecting content of apoc3 protein in preparation of reagent for predicting development of oocytes |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huang et al. | Oestrogen‐induced angiogenesis promotes adenomyosis by activating the S lug‐VEGF axis in endometrial epithelial cells | |
Catalano et al. | Downregulated IRS-1 and PPARγ in obese women with gestational diabetes: relationship to FFA during pregnancy | |
CN113577047A (en) | Application of preparation for regulating and controlling expression level of ApoC3 in preparation of medicine for preventing or treating insulin-resistant polycystic ovarian syndrome | |
US8067364B2 (en) | Deer antler extract for promoting angiogenesis | |
Baraskar et al. | Female obesity: association with endocrine disruption and reproductive dysfunction | |
Zhou et al. | Altered expressions of AQP3 and ADP are closely related with the risk of preeclampsia occurrence | |
Li et al. | Activation of C3 and C5 May Be Involved in the Inflammatory Progression of PCM and GM | |
Thomas et al. | Alternative splicing of IGF1 gene as a potential factor in the pathogenesis of Peyronie's disease | |
Li et al. | Talin1 regulates glucose metabolism and endometrial receptivity via GLUT-4 in patients with polycystic ovary syndrome and insulin resistance | |
Yuan et al. | Angiopoietin‐Like 8 in Gestational Diabetes Mellitus: Reduced Levels in Third Trimester Maternal Serum and Placenta, Increased Levels in Cord Blood Serum | |
Gök et al. | Evaluation of the adipokine levels of pregnant women with preeclampsia | |
Ren et al. | [Retracted] Effects of Different Ovulation Induction Regimens on Sex Hormone Levels and Serum CTRP3 and CTRP15 Levels in Patients with Polycystic Ovary Syndrome (PCOS) | |
Wang et al. | Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats | |
JP2011529924A (en) | Use of sophoricoside for the manufacture of pharmaceuticals | |
de O Mendes-Aguiar et al. | Dual Role of Insulin‐Like Growth Factor (IGF)‐I in American Tegumentary Leishmaniasis | |
Matsuzaki et al. | Expression of WT1 is down-regulated in eutopic endometrium obtained during the midsecretory phase from patients with endometriosis | |
Yu et al. | Amelioration of NAFLD by sleeve gastrectomy-triggered hepatocyte regeneration in mice–experimental research | |
Meng et al. | Activation of estrogen receptor α inhibits TLR4 signaling in macrophages and alleviates the instability of atherosclerotic plaques in the postmenopausal stage | |
CN111481535A (en) | Application of IDHP in preparation of anti-septicemia and myocardial damage drug induced by IDHP | |
CN114959012B (en) | Product for detecting tendon injury | |
Attia et al. | Metformin decreases the expression of VEGF-A and CTGF-1 and improves histological, ultrastructural and hormonal changes in adult rat polycystic ovary | |
CN109700791B (en) | Application of neosinomenine in preparing medicine for treating benign prostatic hyperplasia | |
Ismail et al. | Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats | |
Mansoor et al. | THE ASSOCIATION OF SERUM LEVEL OF IRISIN AND UROTENSIN II WITH INSULIN RESISTANCE IN PATIENTS WITH PREECLAMPSIA. | |
WO2023241565A1 (en) | Use of reagent for detecting content of apoc3 protein in preparation of reagent for predicting development of oocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |
|
RJ01 | Rejection of invention patent application after publication |